The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase II – A071702
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma
Alliance for Clinical Trials in Oncology
Dunn, Gavin Peter
(314) 747-6141
Phase II – EAQ191
Cancer Therapy Risk-Reduction with Intensive Systolic BP Management (CARISMA) – a Phase II Study
ECOG-ACRIN Cancer Research Group
Ky, Bonnie
(215) 573-6606
Phase II – S1905
A Phase II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)
SWOG
Advani, Anjali S.
(216) 445-9354
Phase III – EA5181
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
ECOG-ACRIN Cancer Research Group
Pennell, Nathan Adam
(216) 445-9282
